-
Naloxegol (INN;
PEGylated naloxol;
trade names Movantik and Moventig) is a
peripherally acting μ-opioid
receptor antagonist developed by AstraZeneca, licensed...
-
sublicense its
global rights (except Europe,
Canada and Israel) to the drug
Movantik, to
Redhill Biopharma. In June 2020,
AstraZeneca made a
preliminary approach...
-
biologic drug candidates. Its drug
candidate base
consists of
naloxegol (
Movantik), a
Phase III oral
opioid antagonist,
etirinotecan pegol, a topoisomerase...
- 42: 94–97. doi:10.1016/j.ijscr.2017.11.060. PMC 5730425. PMID 29232630. "
Movantik for the
Treatment of Opioid-Induced Constipation".
Clinical Trials Arena...
- doi:10.1111/pme.12911. PMID 26461071. "Press
Announcements - FDA
approves Movantik for opioid-induced constipation". www.fda.gov.
Archived from the original...
- with
relapsing forms of
multiple sclerosis. (Biogen, 2014)
Naloxegol (
Movantik) –
PEGylated naloxol for the
treatment of opioid-induced
constipation in...
-
effects in patients,
while treating constipation)
Naloxegol (trade
names Movantik and Moventig) -
another peripherally selective opioid antagonist used to...
- Pain/Gastrointestinal, Ophthalmic, Women's
Health and Oncology. Its
marketed products are
Movantik for the
treatment of opioid-induced constipation, Probuphine, a sub-dermal...
- Wael; Hovsepyan, Karen; You, Jing. "Ancillary
Effects of Oral
Naloxegol (
Movantik)" (PDF). Clinicaltrials.gov. "Methylnaltrexone bromide". pubchem.ncbi.nlm...
